CORALABPharmaceuticals
Coral Laboratories Ltd — Cash Flow Statement
₹370.55
-4.99%
Coral Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -4.17 Cr | -6.46 Cr | 10.72 Cr | 0.54 Cr | — |
| Capital Expenditure | -2.94 Cr | -0.99 Cr | -1.95 Cr | -5.55 Cr | — |
| End Cash Position | 3.41 Cr | 2.07 Cr | 6.13 Cr | 2.51 Cr | — |
| Beginning Cash Position | 2.07 Cr | 6.13 Cr | 2.51 Cr | 2.32 Cr | — |
| Changes In Cash | 1.33 Cr | -4.06 Cr | 3.62 Cr | 0.18 Cr | — |
| Financing Cash Flow | 2.71 Cr | 66000.00 | -6.43 Cr | 0.15 Cr | — |
| Interest Paid Cff | -0.10 Cr | -2000.00 | -0.34 Cr | -0.14 Cr | — |
| Cash Dividends Paid | -0.71 Cr | — | — | — | — |
| Net Issuance Payments Of Debt | 3.52 Cr | 68000.00 | -6.09 Cr | 0.29 Cr | — |
| Net Long Term Debt Issuance | 3.52 Cr | 68000.00 | -6.09 Cr | 0.29 Cr | — |
| Investing Cash Flow | -0.15 Cr | 1.40 Cr | -2.61 Cr | -6.05 Cr | — |
| Net Other Investing Changes | -1.90 Cr | -1.36 Cr | -0.94 Cr | -0.61 Cr | — |
| Interest Received Cfi | 4.84 Cr | 3.36 Cr | 1.79 Cr | 1.75 Cr | — |
| Dividends Received Cfi | 0.28 Cr | 0.21 Cr | 0.21 Cr | 0.39 Cr | — |
| Net Investment Purchase And Sale | -0.43 Cr | 0.18 Cr | -1.73 Cr | -2.03 Cr | — |
| Sale Of Investment | 0.00 | 0.18 Cr | 0.27 Cr | 0.00 | — |
| Purchase Of Investment | -0.43 Cr | 0.00 | -2.00 Cr | -2.03 Cr | — |
| Net PPE Purchase And Sale | -2.94 Cr | -0.99 Cr | -1.95 Cr | -5.55 Cr | — |
| Sale Of PPE | 0.00 | 0.00 | — | — | 0.00 |
| Purchase Of PPE | -2.94 Cr | -0.99 Cr | -1.95 Cr | -5.55 Cr | — |
| Operating Cash Flow | -1.22 Cr | -5.46 Cr | 12.67 Cr | 6.08 Cr | — |
| Taxes Refund Paid | -7.33 Cr | -4.88 Cr | -1.97 Cr | -4.37 Cr | — |
| Change In Working Capital | -24.12 Cr | -19.51 Cr | 6.06 Cr | -0.44 Cr | — |
| Change In Other Current Liabilities | -0.62 Cr | 1.43 Cr | -2.68 Cr | 3.77 Cr | — |
| Change In Other Current Assets | -17.07 Cr | -17.60 Cr | -7.20 Cr | -7.73 Cr | — |
| Change In Payable | -6.62 Cr | 9.03 Cr | -5.11 Cr | -5.57 Cr | — |
| Change In Inventory | 5.29 Cr | -2.65 Cr | 5.86 Cr | 3.31 Cr | — |
| Change In Receivables | -5.45 Cr | -4.77 Cr | 14.69 Cr | 1.05 Cr | — |
| Other Non Cash Items | -4.74 Cr | -3.36 Cr | -1.45 Cr | -1.61 Cr | — |
| Depreciation And Amortization | 2.01 Cr | 1.98 Cr | 2.18 Cr | 1.99 Cr | — |
| Depreciation | 2.01 Cr | 1.98 Cr | 2.18 Cr | 1.99 Cr | — |
| Gain Loss On Investment Securities | -0.28 Cr | -0.59 Cr | -0.35 Cr | -0.39 Cr | — |
| Net Income From Continuing Operations | 33.24 Cr | 20.90 Cr | 8.19 Cr | 10.90 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -1000.00 | — | — | -1000.00 |
| Amortization Cash Flow | — | 34000.00 | — | — | — |
| Pension And Employee Benefit Expense | — | 0.00 | — | — | — |
| Net Other Financing Charges | — | — | — | -1000.00 | — |
| Issuance Of Debt | — | — | — | — | 0.34 Cr |
| Common Stock Dividend Paid | — | — | — | — | 0.00 |
| Net Short Term Debt Issuance | — | — | — | — | 0.34 Cr |
| Long Term Debt Issuance | — | — | — | — | 0.34 Cr |
| Gain Loss On Sale Of PPE | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Coral Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.